|Back to Home > Events > Media Events > Getting your ADCs to the clinic: Consideration for early stage development|
Getting your ADCs to the clinic: Consideration for early stage development
Dec 2, 2013, 8:30AM to 1:30PM
|Details||The development of existing or novel monoclonal antibodies as drug-conjugates to increase the targeted clinical effect of these proteins has rapidly increased in recent years. Over 30 antibody–drug conjugates (ADCs) are being tested in the clinic in a range of oncology indications.
SMi's masterclass hosted by PAREXEL International will discuss ADCs which are being tested in the clinic in a range of oncology indications. In the absence of specific guidance on the development of ADCs, this workshop aims to help participants understand the CMC issues during the development, with a particular focus on the assessment and control of the quality of such products.
Contact Fateja Begum
Tel: +44 (0) 20 7827 6184
Keywords: clinical studies, phase i, legistlations, cmc, conjugate, antibody, adc, antibody drug conjugate, eu, drug, regulatory, compliance, pharma, workshop, development, strategies.
|Venue||Holiday Inn Bloomsbury|